Citations

Clear

949 citation(s) found for "Li, Bryan".

Structural variants in Lewy body dementia and frontotemporal dementia spectrum
Ding, Jinhui , Rasheed, Memoona, Walton, Ronald L., Brand, Harrison , Zhao, Xuefang , Dewan, Ramita , Solaiman, Sultana , Dawson, Ted M. , Albert, Marilyn S. , Pletnikova, Olga, Troncoso, Juan C. , Masellis, Mario, Keith, Julia , Resnick, Susan M. , Ryten, Mina , Hardy, John , Mazzini, Letizia , Moglia, Cristina, Beach, Thomas G. , Graff‐Radford, Neill R. , Jager, Philip L. De , Hardy, John , Kaivola, Karri , Chia, Ruth , Fujita, Masashi , Menon, Vilas , Collins, Ryan L. , Billingsley, Kimberley J. , Talkowski, Michael E. , Ray, Anindita , Jerez, Pilar Álvarez , Malik, Laksh , Rosenthal, Liana S. , Pletniková, Olga , Black, Sandra E. , Ferrucci, Luigi , Tanaka, Toshiko , Topol, Eric J. , Torkamani, Ali , Tienari, Pentti J. , Foroud, Tatiana , Ghetti, Bernardino , Landers, John E. , Morris, Huw R. , D’Alfonso, Sandra , Moglia, Cristina , Calvo, Andrea , Serrano, Geidy E. , Ferman, Tanis J. , Boeve, Bradley F. , Wszołek, Zbigniew K. , Dickson, Dennis W. , Chiò, Adriano , Bennett, David A. , Ross, Owen A. , Dalgard, Clifton L. , Gibbs, J. Raphael , Traynor, Bryan J. , Scholz, Sonja W.

Mayo Clinic

Alzheimer's & Dementia | December 25, 2023 | Volume: 19 | Issue: S12 | Pages: No page available

10.1002/alz.078497 Get It

AbstractBackgroundStructural variants range from simple loss or gain of genetic material to complex events that restructure entire chromosomes. This heterogeneity coupled with variant size greater than sequencing read‐length makes structural variant mapping from short‐read sequencing data difficult and error‐prone. Consequently, the role of structural variants is poorly explored in many phenotypes, including dementia.MethodWe used the GATK‐SV pipeline that combines four external structural variant mapping algorithms with machine‐learning to build high‐quality consensus structural variant calls. We applied GATK‐SV to short‐read whole‐genome sequencing data of 2,601 frontotemporal dementia‐amyotrophic lateral sclerosis spectrum (FTD/ALS) patients, 2,612 Lewy body dementia (LBD) patients, and 4,132 neurologically unaffected participants.ResultAfter stringent quality‐control, we performed genome‐wide association studies on 2,307 ALS/FTD patients versus 3,677 controls with 4,699 common structural variants and 2,355 LBD patients versus 3,700 controls with 4,889 common structural variants. In the FTD/ALS cohort, we identified well‐known risk variants at the C9orf72 (p‐value = 4.99×10‐18, OR = 14.47, 95% CI = 7.90–26.49) and MAPT loci (p‐value = 3.48×10‐6, OR = 0.77, 95% CI = 0.68–0.86) corroborating the ability of our pipeline to identify disease‐associated structural variants. Moreover, we discovered, replicated, and validated TPCN1 as a novel risk locus for LBD (p‐value = 9.18×10‐6, OR = 1.43, 95% CI = 1.22–1.67). Further, we identified rare exonic variants with known pathogenic or likely pathogenic effects, such as an SNCA gene duplication in LBD and a deletion of exons 1 and 2 in CHCHD10 in FTD/ALS. We additionally observed structural variants in regulatory regions, e.g. a deletion of a key PSEN2 enhancer, which resulted in an approximate 0.70 fold‐change in PSEN2 expression in LBD. Finally, we built an interactive web app where structural variants can be visualized and explored (https://ndru-ndrs-lng-nih.shinyapps.io/non_ad_dementias_sv_app/).ConclusionCommon and rare structural variants play a role in LBD and FTD/ALS. Our structural variant resource is publicly available and can be used to further explore the role of structural variants in LBD and FTD/ALS.
Abstract 12815: The Effect of Altitude on Cardiovascular Disease Mortality: Insights From a National Database in Ecuador
Nicolalde, Bryan , Serpa, Frans, Arteaga, Deisy Muriel Velez, Zuniga, Angelo Nicolas Caputi, ARIAS, XIMENA, Serpa, Frans , Zuniga, Angelo Caputi, Añazco, Diego

Mayo Clinic

Circulation | December 19, 2023 | Volume: 148 | Issue: Suppl_1 | Pages: No page available

10.1161/circ.148.suppl_1.12815 Get It

Introduction: Cardiovascular disease (CVD) is a leading cause of mortality worldwide. European population studies have shown a protective effect of high altitude on CVD mortality, but the applicability of these findings to Latin population remains to be explored. We aim to compare the mortality rates from ischemic heart disease (IHD), heart failure (HF), and cardiac arrhythmias between low- and high-altitude regions in Ecuador. Hypothesis: CVD mortality might be influenced by altitude Methods: We collected nationwide mortality data on different CVDs for each canton in Ecuador from 2017 to 2021 by using pre-defined ICD-10 codes. Then, we collected the mean altitude in meters above sea level (ASL) for each specific canton and classified them into low-(<2500 meters ASL) and high-altitude (>2500 meters ASL) cantons. We estimated the aggregated mortality rates per 100.000 persons and 95% confidence interval for high- and low-altitude regions at each timepoint. Results: From 2017 to 2021, 69.002 deaths due to CVDs occurred in Ecuador (IHD: 77.0%, HF:19.8% and cardiac arrhythmias: 3.2%). Mean age at death across different pathologies ranged between 76 and 81 years old, and most participants identified as multi-ethic (Table 1). There was a significantly higher mortality rate for HF and cardiac arrhythmias in high-altitude cantons than in low-altitude cantons at almost all timepoints (Figure 1). The mortality rates for IHD were lower for high-altitude cantons than low-altitude cantons at all timepoints. Conclusions: High-altitude cantons in Ecuador had higher mortality rates for HF and cardiac arrhythmias, but lower mortality rates for IHD when compared to low-altitude cantons.
Abstract 12814: Impact of Obesity on Catheter Ablation of Ventricular Tachycardia in the United States: In-Hospital and 30-day Outcomes
Ang, Qi Xuan , Tan, Jian Liang , Tan, Min Choon , Yeo, Yong Hao , Tan, Bryan E‐Xin , Rattanawong, Pattara , Lee, Justin

Mayo Clinic

Circulation | December 19, 2023 | Volume: 148 | Issue: Suppl_1 | Pages: No page available

10.1161/circ.148.suppl_1.12814 Get It

Background: Catheter ablation for ventricular tachycardia (VT) has been increasingly performed. While it is estimated that 42% of adults in the United States are obese, the impact of obesity on VT ablation procedures remains unclear. Objective: This study aimed to evaluate the procedural outcomes and 30-day readmission among non-obese and obese patients who underwent catheter ablation of VT. Method: Using the Nationwide Readmissions Database, our study included patients aged 18 years or older who underwent catheter ablation for VT between 2017 and 2020. The study cohort was stratified into non-obese (BMI < 30kg/m 2 ) and obese (BMI ≥ 30kg/m 2 ). The in-hospital procedural outcome and 30-day readmission were analyzed between these groups. Results: Our study included a total of 835 obese patients (19.7%) and 3393 non-obese patients (80.3%). Obese group had a higher rate of prolonged length of stay (>7 days) (37.6% vs 31.2%, p<0.01) and a higher cost of hospitalization ($39 983 vs $37 015, p<0.01). Overall, there were no significant differences in early mortality (4.5% vs 3.8%, p=0.45). Apart from increased vascular complications in the obese group (1.8% vs 0.9%, p=0.03), there were no significant differences in other procedural complications between both groups. There were no significant differences in 30-day readmission rates between obese and non-obese groups (15.5% vs 14.1%, p=0.38). Additional analysis performed in the obese group revealed a non-significant decreasing trend in early mortality rate post-procedurally (5.4% to 4.8%, P trend = 0.66). On multivariable analysis, heart failure was associated with a higher risk of 30-day readmission in obese patients (OR: 2.00; 95% CI: 1.01-3.99; p=0.05). Conclusion: Our study suggests that catheter ablation for VT can be performed relatively safely in obese patients without significant differences in 30-day mortality and readmission outcomes. Patients should not be excluded from VT ablation on the basis of obesity.
Benign Breast Disease and Breast Cancer Risk in the Percutaneous Biopsy Era
Vachon, Celine M. , Carter, Jodi M. , Jensen, Matthew R. , McCauley, Bryan M. , Seymour, Lisa R. , Gehling, Denice, Fischer, Jessica, Ghosh, Karthik, Pacheco-Spann, Laura, Hoskin, Tanya L. , Seymour, Lisa, Radisky, Derek C. , Carter, Jodi , Sherman, Mark E. , Vierkant, Robert A. , Winham, Stacey J. , Vachon, Celine M. , Pacheco-Spann, Laura M. , Degnim, Amy C.

Mayo Clinic

JAMA Surgery | December 13, 2023 | Volume: 159 | Issue: 2 | Pages: 193

10.1001/jamasurg.2023.6382 | PMID 38091020 Get It

Importance Benign breast disease (BBD) comprises approximately 75% of breast biopsy diagnoses. Surgical biopsy specimens diagnosed as nonproliferative (NP), proliferative disease without atypia (PDWA), or atypical hyperplasia (AH) are associated with increasing breast cancer (BC) risk; however, knowledge is limited on risk associated with percutaneously diagnosed BBD. Objectives To estimate BC risk associated with BBD in the percutaneous biopsy era irrespective of surgical biopsy. Design, Setting, and Participants In this retrospective cohort study, BBD biopsy specimens collected from January 1, 2002, to December 31, 2013, from patients with BBD at Mayo Clinic in Rochester, Minnesota, were reviewed by 2 pathologists masked to outcomes. Women were followed up from 6 months after biopsy until censoring, BC diagnosis, or December 31, 2021. Exposure Benign breast disease classification and multiplicity by pathology panel review. Main Outcomes The main outcome was diagnosis of BC overall and stratified as ductal carcinoma in situ (DCIS) or invasive BC. Risk for presence vs absence of BBD lesions was assessed by Cox proportional hazards regression. Risk in patients with BBD compared with female breast cancer incidence rates from the Iowa Surveillance, Epidemiology, and End Results (SEER) program were estimated. Results Among 4819 female participants, median age was 51 years (IQR, 43-62 years). Median follow-up was 10.9 years (IQR, 7.7-14.2 years) for control individuals without BC vs 6.6 years (IQR, 3.7-10.1 years) for patients with BC. Risk was higher in the cohort with BBD than in SEER data: BC overall (standard incidence ratio [SIR], 1.95; 95% CI, 1.76-2.17), invasive BC (SIR, 1.56; 95% CI, 1.37-1.78), and DCIS (SIR, 3.10; 95% CI, 2.54-3.77). The SIRs increased with increasing BBD severity (1.42 [95% CI, 1.19-1.71] for NP, 2.19 [95% CI, 1.88-2.54] for PDWA, and 3.91 [95% CI, 2.97-5.14] for AH), comparable to surgical cohorts with BBD. Risk also increased with increasing lesion multiplicity (SIR: 2.40 [95% CI, 2.06-2.79] for ≥3 foci of NP, 3.72 [95% CI, 2.31-5.99] for ≥3 foci of PDWA, and 5.29 [95% CI, 3.37-8.29] for ≥3 foci of AH). Ten-year BC cumulative incidence was 4.3% for NP, 6.6% for PDWA, and 14.6% for AH vs an expected population cumulative incidence of 2.9%. Conclusions and Relevance In this contemporary cohort study of women diagnosed with BBD in the percutaneous biopsy era, overall risk of BC was increased vs the general population (DCIS and invasive cancer combined), similar to that in historical BBD cohorts. Development and validation of pathologic classifications including both BBD severity and multiplicity may enable improved BC risk stratification.
Clinicopathological Correlates of Verbal Fluency in Parkinson’s Disease: A Pilot Study (P3.197)
El‐Nazer, Rasheda, Artz, Jonathan , Chen, Wencong , Belden, Christine M. , Adler, Charles, Beach, Thomas G. , Benge, Jared F.

Mayo Clinic

Neurology | December 7, 2023 | Volume: 90 | Issue: 15_supplement | Pages: No page available

10.1212/wnl.90.15_supplement.p3.197 Get It

α-Synuclein in Red Blood Cells Is a Potential Diagnostic Biomarker for Parkinson’s Disease (S37.006)
Savica, Rodolfo , Dyer, Roy B. , Klassen, Bryan T. , Boeve, Bradley, Klee, George G., Ahlskog, J. Eric , Rocca, Walter A. , Mielke, Michelle M. , Ramı́rez-Alvarado, Marina

Mayo Clinic

Neurology | December 7, 2023 | Volume: 82 | Issue: 10_supplement | Pages: No page available

10.1212/wnl.82.10_supplement.s37.006 Get It

Electrical Stimulation of the Anterior and Centromedian Nucleus of Thalamus for Treatment of Refractory Epilepsy _ Report of Four Cases (P7.279)
Hu, Wei , Klassen, Bryan T. , Lee, Kendall, Clayton, Daniel A., Stead, S. Matt, Lee, Kendall H.

Mayo Clinic

Neurology | December 7, 2023 | Volume: 82 | Issue: 10_supplement | Pages: No page available

10.1212/wnl.82.10_supplement.p7.279 Get It

Neurological Examination Findings in Autistic Adults (P2.176)
Woodruff, Bryan K. , Hentz, Joseph G. , Duffy, Amy, Pollard, Elena L., Smith, Christopher, Geda, Yonas E.

Mayo Clinic

Neurology | December 7, 2023 | Volume: 82 | Issue: 10_supplement | Pages: No page available

10.1212/wnl.82.10_supplement.p2.176 Get It

α-Synuclein in Red Blood Cells Is a Potential Diagnostic Biomarker for Parkinson’s Disease (1II-2.003)
Savica, Rodolfo , Dyer, Roy B. , Klassen, Bryan T. , Boeve, Bradley, Klee, George G., Ahlskog, J. Eric , Rocca, Walter A. , Mielke, Michelle M. , Ramı́rez-Alvarado, Marina

Mayo Clinic

Neurology | December 7, 2023 | Volume: 82 | Issue: 10_supplement | Pages: No page available

10.1212/wnl.82.10_supplement.1ii-2.003 Get It

Factors Related to Higher Neurobiological Capital Across the Lifespan: Mayo Clinic Study of Aging (S34.002)
Graff‐Radford, Jonathan , Przybelski, Scott A. , Petersen, Ronald, Jack, Clifford, Neth, Bryan J. , Schwarz, Christopher G. , Reid, Robert I. , Mielke, Michelle M. , Knopman, David S. , Vemuri, Prashanthi

Mayo Clinic

Neurology | December 7, 2023 | Volume: 92 | Issue: 15_supplement | Pages: No page available

10.1212/wnl.92.15_supplement.s34.002 Get It